Global Lutetium-177 Market Size is valued at USD 2.11 Bn in 2024 and is predicted to reach USD 7.41 Bn by the year 2034 at a 11.6% CAGR during the forecast period for 2025-2034.
Lutetium-177 (Lu-177) is a radioactive isotope employed in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. Being a medium-energy beta emitter with a half-life of 6.7 days, it targets regional radiation with minimal injury to normal tissues. Lu-177 is manufactured in two types: Non-Carrier-Added (NCA) Lu-177, which has high purity and high specific activity, a requirement for precision medicine, and Carrier-Added (CA) Lu-177, a cheaper but lower specific activity type with proven production processes.
It is used in peptide receptor radionuclide therapy (PRRT) and PSMA-directed therapies, as well as in radiopharmaceutical research and nuclear medicine. One of the main drivers of the Lu-177 market is the growing need for targeted radiotherapy solutions in the face of escalating global cancer incidence. With healthcare providers looking for effective treatments with fewer side effects, the precision and effectiveness of Lu-177 make it a go-to option. Moreover, advancements in nuclear medicine and supportive regulatory frameworks also propel its uptake, ensuring sustained market growth and innovation in cancer therapy.
Competitive Landscape
Some of the Key Players in Lutetium-177 Market:
- Novartis AG
- Curium
- Telix Pharmaceuticals
- ITM Isotope Technologies
- Eli Lilly (via POINT Biopharma)
- Radiopharm Theranostics
- Advanced Accelerator Applications (AAA)
- Evergreen Theragnostics
- Nusano Inc.
- Nordic Nanovector
Market Segmentation:
The lutetium-177 market is segmented by application, type, product type, scale of operation, end user, production, technology. By application, the market is segmented into oncology, non-oncology. Oncology is sub segmented mCRPC, NETs, RCC, and other cancers. Non-oncology is sub segmented into arthritis, other. By type market is segmented into carrier-added lutetium-177, no-carrier-added lutetium-177. By Product type the market is segmented into approved drugs, pipeline drugs, investigational drugs. Approved Drugs is sub segmented into, Pluvicto (Pro), Lutathera (Pro). By scale of operation the market is segmented into preclinical, clinical, commercial. By end-user the market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, research institutions/CROs. By production the market is segmented into reactor-based, cyclotron-based. By technology, the market is segmented into targeting ligands, production innovations, combination therapies.
Targeting Ligands Segment is Expected to Drive the Lutetium-177 Market
The market for lutetium-177 (Lu-177) is largely driven by targeting ligands, which allow beta radiation to be precisely delivered to cancer cells while avoiding damage to healthy tissue. By attaching to tumor-specific receptors, these ligands—peptides, antibodies, or small molecules—increase treatment effectiveness and reduce adverse effects. Additionally, their application facilitates a theranostic strategy by enabling imaging to find qualified patients prior to treatment. New ligands for other tumors have been developed as a result of the successful treatment of prostate and neuroendocrine cancers, increasing applications and speeding up market expansion.
No-Carrier-Added (NCA) Lutetium-177 is Growing at the Highest Rate in the Lutetium-177 Market.
The No-Carrier-Added (NCA) Lutetium-177 segment is experiencing significant growth in the Lu-177 market due to its high purity and superior specific activity. Produced via the indirect method by irradiating ytterbium-176 (Yb-176), NCA Lu-177 lacks Lu-177m, resulting in a purer product with enhanced therapeutic concentrations and reduced radioactive waste. Its higher efficacy and minimal side effects make it the preferred choice for targeted therapies such as peptide receptor radionuclide therapy (PRRT) and PSMA-targeted treatments, driving its increasing adoption in precision cancer treatment.
Regionally, North America Led the Lutetium-177 Market.
North America dominates the Lutetium-177 (Lu-177) market due to its sophisticated healthcare infrastructure, high incidence of cancer, and robust research and development efforts. The region's advanced medical facilities enable the extensive use of Lu-177 therapies for the treatment of neuroendocrine tumors and prostate cancer. North America is also home to many pharmaceutical and biotech firms involved in cancer research, which encourages innovation and drives the uptake of Lu-177 in targeted radionuclide therapies.
Lutetium-177 Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 2.11 Bn |
|
Revenue forecast in 2034 |
USD 7.41 Bn |
|
Growth Rate CAGR |
CAGR of 11.6% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2034 |
|
Historic Year |
2021 to 2023 |
|
Forecast Year |
2024-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, Type, Product Type, Scale of Operation, End User, Production, Technology and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Novartis AG, Curium, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), Radiopharm Theranostics, Advanced Accelerator Applications (AAA), Evergreen Theragnostics, Nusano Inc., Nordic Nanovector |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
